EBR SYSTEMS INC (EBR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBR

EBR - EBR SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.24
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.65

24 Apr
2026

0.050

OPEN

$0.63

8.33%

HIGH

$0.66

835,342

LOW

$0.61

TARGET
$2.235 243.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
EBR: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 13.2 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-18.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx2.5 M
Book Value Per Share xxxxxxxxxxxxxxx8.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-82.5 M
Net Profit Margin xxxxxxxxxxxxxxx-3,015.34 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-194.61 %
Return on Invested Capital xxxxxxxxxxxxxxx-65.82 %
Return on Assets xxxxxxxxxxxxxxx-57.15 %
Return on Equity xxxxxxxxxxxxxxx-194.61 %
Return on Total Capital xxxxxxxxxxxxxxx-61.50 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-88.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx86 M
Total Debt xxxxxxxxxxxxxxx88 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx80 M
Price To Book Value xxxxxxxxxxxxxxx10.50

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx5.7 M
Capex % of Sales xxxxxxxxxxxxxxx227.77 %
Cost of Goods Sold xxxxxxxxxxxxxxx2 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx72 M
Research & Development xxxxxxxxxxxxxxx37 M
Investments - Total xxxxxxxxxxxxxxx5 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

09/04/2026

1

Buy

$2.00

207.69%

Bell Potter highlights strong preliminary 1Q26 metrics released today by EBR Systems, with implants of 41 more than doubling quarter-on-quarter. Revenue also more than doubled to US$2.3m.

At first glance, the broker feels growth was supported by increased hospital contracts, physician training, and improving utilisation of the WiSE leadless cardiac pacing system.

Average selling prices rose around 10% to US$56,098, exceeding the analyst's expectations, while adoption trends remain positive across both volume and usage.

With further sales team expansion expected to support growth from 2Q26, Bell Potter sees continued momentum building investor confidence.

Buy rating. Target of $2.00.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -14.69 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -13.04 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

22/04/2026

1

Buy

$2.43

273.85%

Canaccord Genuity maintains a Buy rating and $2.43 target price for EBR Systems following recent clinical updates for the WiSE-CRT system.

A new case report demonstrates the first successful use of WiSE technology alongside Abbott's leadless pacemaker in the US for a non-responsive heart failure patient.

The analyst observes the leadless pacemaker market is growing faster than internal assumptions, validating the company's strategic focus.

Recent studies show conduction system pacing provides superior outcomes compared to traditional methods, highlighting potential new use cases for the septal electrode.

While this update focuses on technical milestones, the broker believes off-label usage in the US further validates clinical utility ahead of broader label expansion.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
Access Extra Coverage Research History >

EBR STOCK CHART

FNArena News on EBR

1
Rudi’s View: Best Buys & Conviction Calls

Apr 23 2026 - Rudi's View
2
Australian Broker Call *Extra* Edition – Apr 22, 2026

Apr 22 2026 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Apr 14, 2026

Apr 14 2026 - Daily Market Reports
4
Rudi’s View: Strategists Touting Opportunities

Apr 02 2026 - Rudi's View
5
FNArena Corporate Results Monitor – 25-03-2026

Mar 25 2026 - Australia

Latest Medical Equipment & Devices News

1
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
2
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
3
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
4
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
5
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
6
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
7
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
8
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
9
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
10
ResMed’s New Level Of Support

Jul 29 2025 - Technicals